Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition
Background: Alendronate (ALN), a nitrogen-containing bisphosphonate, is prescribed to treat bone diseases. ALN acts as an inhibitor of enzymes in the mevalonate pathway, which results in reducing osteoblast viability and mineralization. Geranylgeraniol (GGOH) is a substrate in mevalonate pathway and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | Journal of Oral Biology and Craniofacial Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221242682100049X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|